View Clinical Trial (Medical Research Study)
Ovarian Reserve Testing in Female Young Adult Cancer Survivors
| City: |
|
San Diego |
| State: |
|
California |
| Zip Code: |
|
91351 |
| Conditions: |
|
Cancer - Infertility |
| Purpose: |
|
Young adult cancer survivors constitute an under served population to whom fertility
potential is particularly important. For female young adult patients, cancer treatment such
as alkylating chemotherapy are toxic to the finite number of eggs they have, resulting in
risks of infertility and premature menopause related to ovarian failure. Reproductive issues
are a major concern for young cancer survivors, but one that is understudied. Young cancer
survivors have few tools to measure post-treatment ovarian reserve, or the quantity and
quality of remaining eggs4. Accurate determination of ovarian reserve and fertility
potential would not only be an important research tool, but also directly impact clinical
management. The purpose of this study is to test if basal and provocative ovarian reserve
testing can predict return of menses in female young adult cancer survivors, to compare
basal and provocative ovarian reserve testing results between female young adult cancer
survivors and healthy controls, and to compare basal and provocative ovarian reserve testing
results between female young adult cancer survivors on and off of combined estrogen and
progesterone hormone products.
Participants will be asked to keep track of their periods over three months. If a
participant is taking birth control pills, patches, or vaginal ring, they will asked to come
off the birth control for 3 months. Participants will also be asked to undergo ovarian
reserve testing by blood draws and pelvic ultrasounds at the start and end of the 3 months.
|
| Study Summary: |
|
Same as brief summary
|
| Criteria: |
|
Inclusion Criteria:
- Postmenarchal
- Cancer diagnosis
- Prior exposure to gonadotoxic therapy, inclusive of chemothearpy, pelvic or total
body irradiation, unilateral oophorectomy
- A minimum of 1 year since completion of gonoadotoxic therapy
- Intact uterus
- At least one ovary
Exclusion Criteria:
- Estrogen receptor positive cancers
|
| NCT ID: |
|
NCT01421095 |
| Primary Contact: |
|
Principal Investigator
H. Irene Su, MD MSCE
UC San Diego
Samantha C Bailey
Phone: 858-822-0768
Email: ayastudy.ucsd@gmail.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
San Diego, California 91351
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|